Travere therapeutics announces full fda approval of filspari® (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in iga nephropathy

Fda approves expanded indication making filspari available to patients with iga nephropathy (igan) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years conversion to full approval based on results from the protect study, where filspari delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only phase 3 head-to-head trial conducted in igan as an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, filspari has the potential to become foundational care in igan company to host conference call september 5, 2024, at 6 p.m.
TVTX Ratings Summary
TVTX Quant Ranking